Assessment of Patients with Intracerebral Hemorrhage during the Pandemic COVID-19 Learning from Experience
Creators
- 1. M.D. (Medicine), DM (Neurology), Consultant Neurologist, Paras HMRI Hospital, Patna, Bihar, India
Description
Aim: We assessed the patients with intracerebral hemorrhage during the pandemic Covid 19. Methods: The study protocol was approved by the Hospital COVID- 19 Paras HMRI Hospital, Patna, Bihar, India. All research was performed in accordance with guidelines and regulations, and the respective authors declare a statement confirming that informed consent was obtained from all of the participants’ parents and/or their legal guardians. Overall, a total of 50 patients from the PANDEMIC registry fulfilled the inclusion criteria. Results: The demographic and clinical characteristics of patients from the PANDEMIC registry, as well as the results for all individual-level patient data (total n = 100, with n = 50 from the PANDEMIC registry. Conclusion: ICH in COVID-19 patients is rare, but it has a very poor prognosis. Different subtypes of ICH seen in COVID-19, support the assumption of heterogeneous and multifaceted pathomechanisms contributing to ICH in COVID-19. Further clinical and pathophysiological investigations are warranted to resolve the conflict between thromboembolic and hemorrhagic complications in the future.
Abstract (English)
Aim: We assessed the patients with intracerebral hemorrhage during the pandemic Covid 19. Methods: The study protocol was approved by the Hospital COVID- 19 Paras HMRI Hospital, Patna, Bihar, India. All research was performed in accordance with guidelines and regulations, and the respective authors declare a statement confirming that informed consent was obtained from all of the participants’ parents and/or their legal guardians. Overall, a total of 50 patients from the PANDEMIC registry fulfilled the inclusion criteria. Results: The demographic and clinical characteristics of patients from the PANDEMIC registry, as well as the results for all individual-level patient data (total n = 100, with n = 50 from the PANDEMIC registry. Conclusion: ICH in COVID-19 patients is rare, but it has a very poor prognosis. Different subtypes of ICH seen in COVID-19, support the assumption of heterogeneous and multifaceted pathomechanisms contributing to ICH in COVID-19. Further clinical and pathophysiological investigations are warranted to resolve the conflict between thromboembolic and hemorrhagic complications in the future.
Files
IJPCR,Vol15,Issue1,Article181.pdf
Files
(292.4 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:1a49a3369a6294ab920c2b6c43d0d396
|
292.4 kB | Preview Download |
Additional details
Dates
- Accepted
-
2022-11-20
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/15/IJPCR,Vol15,Issue1,Article181.pdf
- Development Status
- Active
References
- 1. Helms J, Kremer S, Merdji H, ClereJehl R, Schenck M, Kummerlen C, Collange O, Boulay C, Fafi-Kremer S, Ohana M, Anheim M. Neurologic features in severe SARS-CoV-2 infection. New England Journal of Medicine. 2020 Jun 4;382(23):2268- 70. 2. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA neurology. 2020 Jun 1;77(6):683-90. 3. Chen X, Laurent S, Onur OA, Kleineberg NN, Fink GR, Schweitzer F, Warnke C. A systematic review of neurological symptoms and complications of COVID-19. Journal of neurology. 2021 Feb; 268:392-402. 4. Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, De Leacy RA, Shigematsu T, Ladner TR, Yaeger KA, Skliut M. Large-vessel stroke as a presenting feature of Covid-19 in the young. New England Journal of Medicine. 2020 May 14;382(20): e60. 5. Morassi M, Bagatto D, Cobelli M, D'Agostini S, Gigli GL, Bnà C, Vogrig A. Stroke in patients with SARS-CoV-2 infection: case series. Journal of neurology. 2020 Aug; 267 :2185-92. 6. Benussi A, Pilotto A, Premi E, Libri I, Giunta M, Agosti C, Alberici A, Baldelli E, Benini M, Bonacina S, Brambilla L. Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy. Neurology. 2020 Aug 18;95(7): e910-20. 7. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, MochH. Endothelial cell infection and endotheliitis in COVID-19. The Lancet. 2020 May 2;395(10234):1417- 8. 8. Koralnik IJ, Tyler KL. COVID-19: a global threat to the nervous system. Annals of neurology. 2020 Jul;88(1):1- 1. 9. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, Chen H, Ding X, Zhao H, Zhang H, Wang C. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. New England Journal of Medicine. 2020 Apr 23;382(17): e38. 10. Divani AA, Andalib S, Di Napoli M, Lattanzi S, Hussain MS, Biller J, McCullough LD, Azarpazhooh MR, Seletska A, Mayer SA, Torbey M. Coronavirus disease 2019 and stroke: clinical manifestations and pathophysiological insights. Journal of Stroke and Cerebrovascular Diseases. 2020 Aug 1;29(8):104941. 11. Kannan S. Shai Syed Ali P, Sheeza A, Hemalatha K. COVID-19. 12. Bohn MK, Hall A, Sepiashvili L, Jung B, Steele S, Adeli K. Pathophysiology of COVID-19: mechanisms underlying disease severity and progression. Physiology. 2020 Sep 1;35(5):288- 301. 13. Benger M, Williams O, Siddiqui J, Sztriha L. Intracerebral haemorrhage and COVID-19: Clinical characteris - tics from a case series. Brain, Behavior, and Immunity. 2020 Aug 1; 88:940-4. 14. Wang X, Ding YQ. From SARS to COVID-19: pathogens, receptor, pathogenesis and principles of the treatment. Zhonghua bing li xue za zhi= Chinese journal of pathology. 2020 Jun 1;49(6):647-52. 15. Abadie V, Jacquin A, Daubail B, Vialatte AL, Lainay C, Durier J, Osseby GV, Giroud M, Bejot Y. Prevalence and prognostic value of headache on early mortality in acute stroke: the Dijon Stroke Registry. Cephalalgia. 2014 Oct;34(11):938-9. 16. Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, Klauber J, Janssens U, Marx G, Weber-Carstens S, Kluge S. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. The Lancet Respiratory Medicine. 2020 Sep 1;8(9):853-62. 17. Melmed KR, Cao M, Dogra S, Zhang R, Yaghi S, Lewis A, Jain R, Bilaloglu S, Chen J, Czeisler BM, Raz E. Risk factors for intracerebral hemorrhage in patients with COVID-19. Journal of thrombosis and thrombolysis. 2021 May; 51:953-60. 18. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Archives of internal medicine. 2004 Apr 26;164(8): 880-4. 19. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. Jama. 2020 May 26;323(20):2052-9. 20. Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, Sánchez-Larsen Á, Layos-Romero A, García-García J, González E, Redondo-Peñas I, PeronaMoratalla AB, Del Valle-Pérez JA, Gracia-Gil J. Neurologic manifestat - ions in hospitalized patients with COVID-19: The ALBACOVID registry. Neurology. 2020 Aug 25;95 (8): e1060-70. 21. Lang CN, Dettinger JS, BerchtoldHerz M, Utzolino S, Bemtgen X, Zotzmann V, Schmid B, Biever PM, Bode C, Müller-Peltzer K, Duerschmied D. Intracerebralhemorrhage in COVID-19 patients with pulmonary failure: a propensity score-matched registry study. Neurocritical care. 2021 Jun; 34:739- 47. 22. Essad Ayoub, Atbib Y., Berdi Fadoua, Tadlaoui Y., & Bousliman Y. Hépatotoxicité médicamenteuse: synergie d'action hépatotoxique des antirétroviraux, des antituberculeux, et d'antifongiques. Journal of Medical Research and Health Sciences. 2022; 5(7): 2064–2071.